Want to see JBIO full AI Analyst Report?
Top Page
Jade Biosciences
(NASDAQ:JBIO)
Select Model
Select Model
Rating:45Neutral
Price Target:
$14.00
▼(-35.90% Downside)
Action:Reiterated
Date:09/30/26
The score is primarily weighed down by weak financial performance (no revenue, expanding losses, and worsening cash burn) and a bearish technical setup (below all key moving averages with negative momentum). Positive pipeline-oriented corporate updates provide some support, but do not offset the near-term funding and trend risks.
Positive Factors
Very low leverage and strong capitalization
Extremely low debt relative to equity gives Jade substantial financial flexibility while it advances its development programs. Strong capitalization can reduce balance-sheet pressure, support continued research investment, and provide greater resilience than a similarly unlevered development-stage biotech.
Negative Factors
Pre-revenue model with widening losses
Jade has no commercial revenue to absorb its operating costs, while losses have expanded materially from prior years. Until a candidate generates revenue, the company remains dependent on capital resources and successful clinical execution to establish a sustainable earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage and strong capitalization
Extremely low debt relative to equity gives Jade substantial financial flexibility while it advances its development programs. Strong capitalization can reduce balance-sheet pressure, support continued research investment, and provide greater resilience than a similarly unlevered development-stage biotech.
Read all positive factors
Jade Biosciences (JBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$915.17M
Dividend Yield23.67%
Average Volume (3M)961.06K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue GrowthN/A
EPS Growth91.41%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.75
Shares Outstanding63,597,385
10 Day Avg. Volume879,576
30 Day Avg. Volume961,057
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.78K
Enterprise Value/Ebitda-5.73
Forecast
1Y Price Target
$50.50Price Target Upside131.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
Jade Biosciences Business Overview & Revenue Model
Company Description
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Ind...
Jade Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.00K | 0.00 | -282.00K | -96.00K | -68.00K | -15.00K |
| EBITDA | -156.28M | -127.33M | -69.29M | -75.37M | -51.42M | -22.95M |
| Net Income | -153.24M | -127.41M | -69.63M | -75.52M | -51.51M | -22.96M |
Balance Sheet | ||||||
| Total Assets | 472.11M | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M |
| Cash, Cash Equivalents and Short-Term Investments | 461.20M | 336.16M | 78.62M | 122.44M | 129.22M | 167.38M |
| Total Debt | 628.00K | 724.00K | 417.00K | 675.00K | 1.09M | 574.00K |
| Total Liabilities | 32.20M | 17.26M | 3.90M | 17.96M | 8.56M | 2.94M |
| Stockholders Equity | 439.92M | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M |
Cash Flow | ||||||
| Free Cash Flow | -123.57M | -94.89M | -71.20M | -56.92M | -39.32M | -27.58M |
| Operating Cash Flow | -123.51M | -94.69M | -71.20M | -56.78M | -39.12M | -27.40M |
| Investing Cash Flow | -352.97M | -247.01M | 56.03M | 11.88M | 6.93M | -113.43M |
| Financing Cash Flow | 362.89M | 360.77M | 25.43M | 46.00M | 396.00K | 190.46M |
Jade Biosciences Technical Analysis
Negative
21.84
Price Trends
18.87
Negative
19.40
Negative
18.27
Negative
Market Momentum
-1.45
Negative
34.14
Neutral
57.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JBIO, the sentiment is Negative. The current price of 21.84 is above the 20-day moving average (MA) of 15.20, above the 50-day MA of 18.87, and above the 200-day MA of 18.27, indicating a bearish trend. The MACD of -1.45 indicates Negative momentum. The RSI at 34.14 is Neutral, neither overbought nor oversold. The STOCH value of 57.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JBIO.
Jade Biosciences Risk Analysis
Jade Biosciences disclosed 74 risk factors in its most recent earnings report. Jade Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jade Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $397.35M | -9.23 | 21.48% | ― | ― | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $112.59M | -0.80 | -938.20% | ― | 159.29% | -7.39% | |
46 Neutral | $456.09M | -5.11 | -35.26% | ― | ― | -13.09% | |
45 Neutral | $915.17M | -5.23 | -49.11% | 23.67% | ― | 91.41% | |
43 Neutral | $26.79M | -0.48 | -98.86% | ― | ― | -33.93% | |
42 Neutral | $91.48M | -1.93 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
JBIO
Jade Biosciences
14.39
5.30
58.31%
GALT
Galectin Therapeutics
3.94
-1.16
-22.75%
IMMP
Immutep
3.63
-36.17
-90.88%
CLLS
Cellectis SA
1.26
-3.16
-71.49%
TECX
Tectonic Therapeutic
23.33
7.24
45.00%
HUMA
Humacyte
0.41
-1.36
-76.99%
Jade Biosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Jade Biosciences advances JADE301 toward Phase 1 trial
Positive
Sep 30, 2026
On September 30, 2026, Jade Biosciences reported preclinical data for JADE301, showing high-affinity and selective interferon beta neutralization with substantially greater potency than a dazukibart comparator in human immune cells and dermal fibr...
Business Operations and Strategy
Jade Biosciences Secures Exclusive Antibody License Agreement
Positive
Jul 1, 2026
On June 29, 2026, Jade Biosciences entered into a worldwide, exclusive license agreement with Paragon Therapeutics for certain monospecific antibodies targeting an undisclosed biological target, covering prophylaxis, palliation, treatment and diag...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.